Ocular Therapeutix, Inc. (OCUL) Return on Equity (ROE) and Return on Assets (ROA)
Ocular Therapeutix, Inc. (OCUL) return on equity (ROE) and return on assets (ROA) history. Calculate ROE/ROA in Excel with MarketXLS.
ROE & ROA Data
| Period | ROE | ROA |
|---|---|---|
| 2016-12-31 | -85.95% | -59.65% |
| 2017-12-31 | -242.42% | -114.35% |
| 2018-12-31 | -167.19% | -82.11% |
| 2019-12-31 | N/A | -109.69% |
| 2020-12-31 | -204.53% | -59.43% |
| 2021-12-31 | -7.45% | -3.20% |
| 2022-12-31 | -200.79% | -47.58% |
| 2023-12-31 | -88.59% | -32.03% |
| 2024-12-31 | -61.36% | -42.26% |
| 2025-12-31 | -40.64% | -32.91% |
Return on equity divides net income by total shareholder equity at the period end. Return on assets divides the same net income by total assets at the period end. A figure reads N/A when the divisor is missing or not positive, because the ratio is not meaningful then.
How OCUL compares with sector peers
| Symbol | Company | Return on equity (latest fiscal year) |
|---|---|---|
| MRNA | Moderna Inc. | -32.62% |
| VKTX | Viking Therapeutics Inc. | -56.28% |
| DMAC | DiaMedica Therapeutics Inc. | -58.39% |
| NTLA | Intellia Therapeutics Inc. | -61.47% |
| ACRS | Aclaris Therapeutics Inc. | -62.98% |
These are five companies in the same sector as OCUL with a comparable annual return on equity. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Ocular Therapeutix, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Return_on_Average_Equity("OCUL", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | OCUL | $9.26 | +0.22% | 0.04M |
| 3 | ||||
| 4 | ||||
| 5 |